pharmaceutical

• 

  How Long Can Advisors Avoid Public Disclosure of Their Conflicts of Interest?

  By Bob Clark, AdvisorOne  |  May 30, 2012

  A ProPublica investigation has revealed the scope of payments to doctors by pharmaceutical companies. Will advisors be next in line for public scrutiny of their finances?

• 

  Fiduciary Debate: What if Doctors Could Act Like Advisors?

  By Bob Clark, AdvisorOne  |  January 16, 2012

  Wherein our intrepid blogger applies the logician's reductio ad absurdum argument to the current debate over applying the fiduciary standard to brokers, or not.

• 

  Emerging Markets Middle Class Is on the Rise, Ready to Spend

  By Nainesh Shah, CFA, Roosevelt Investments  |  January 11, 2012

  The worldwide economic picture may be full of uncertainties but one thing seems likely: the demand for goods and services in the developing world will grow at an unprecedented rate.

• 

  Charitable Giving in U.S. Edged Up to $291B in 2010

  By Michael S. Fischer  |  June 20, 2011

  Total charitable contributions from American individuals, corporations and foundations grew by 3.8% in 2010 in current dollars and 2.1% in inflation-adjusted dollars, according to estimates released Monday by Giving USA Foundation and its research partner, the Center on Philanthropy at Indiana University.

• 

  Transparently Better?

  By Olivia Mellan  |  November 1, 2010

  After the traumatic events of the last few years, some of your clients may be experiencing a crisis of confidence in our economic system, institutions and leaders.

• Biotech/Health Care: Growth Drivers

  By Ed McCarthy, CFP  |  September 1, 2010

  John T. Boris Citigroup Global Markets john.boris@citi.com 212-816-1635 The U.S. major pharmaceutical group is trading at 8.3x (times) 2011 estimated earnings per share (EPS), representing a 32 percent discount...

• Disclaimers

  By Bill Miller  |  June 1, 2010

  Have you noticed that as the baby boom generation ages, the advertising we see on television changes along with them? Think back to those golden...

• 

  Tax Implications

  By Ron Pechtimaldjian, AdvisorOne  |  May 1, 2010

  Taxes are, for a change, probably the easiest area to consider when assessing the implications of healthcare reform for advisors and their clients. To be...

• What's Next for Health Care?

  By Staff Writer  |  May 1, 2010

  The health care sector has never seen anything like this and neither has the American public. After months of political wrangling, the Affordable Health Care for...

• The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform

  By Vaughan Scully, Standard & Poor's  |  April 1, 2010

  Powered by Standard & Poor's MarketScope Advisor While the inability of Congress to form a consensus on how to change the current healthcare system seems to...